family with sequence similarity 86, member CGenealiases: FAM86C · FAM86C1
Q-omics provides the consensus-scored FAM86C1P profile across patient tissues and cancer cell-line models. FAM86C1P expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, FAM86C1P is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, FAM86C1P RNA expression shows 17,301 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, HNSC, and ACC as cancer lineages where FAM86C1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM86C1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM86C1P survival associations across molecular data types. FAM86C1P RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM86C1P RNA expression–survival associations across cancer types. High FAM86C1P expression shows unfavorable associations in LIHC, LGG and BLCA, but favorable associations in OV, BRCA and ESCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for FAM86C1P RNA expression.
This table summarizes FAM86C1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM86C1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM86C1P shows higher tumor expression in HNSC, STAD, COAD, BLCA, LUAD and LIHC. The HNSC box plot shows higher FAM86C1P RNA expression in tumor versus normal tissue (log2 FC = +0.901, t-test p < 0.001).
This table shows molecular features associated with FAM86C1P in patient tissues and cancer cell lines. In patient samples, FAM86C1P shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM86C1P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
